| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PHOX2A |
| Uniprot No | O14813 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-284 aa |
| 活性数据 | MDYSYLNSYD SCVAAMEASA YGDFGACSQP GGFQYSPLRP AFPAAGPPCP ALGSSNCALG ALRDHQPAPY SAVPYKFFPE PSGLHEKRKQ RRIRTTFTSA QLKELERVFA ETHYPDIYTR EELALKIDLT EARVQVWFQN RRAKFRKQER AASAKGAAGA AGAKKGEARC SSEDDDSKES TCSPTPDSTA SLPPPPAPGL ASPRLSPSPL PVALGSGPGP GPGPQPLKGA LWAGVAGGGG GGPGAGAAEL LKAWQPAESG PGPFSGVLSS FHRKPGPALK TNLF |
| 分子量 | 29.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PHOX2A蛋白的3篇参考文献概览，因研究领域较窄，部分文献可能与实际研究方向相关度有限：
---
1. **文献名称**：*PHOX2A mutations in humans result in congenital superior oblique muscle palsy*
**作者**：Yahalom C, et al.
**摘要**：研究首次报道了人类PHOX2A基因突变与先天性动眼神经麻痹的关联，通过重组蛋白功能分析表明突变导致PHOX2A转录调控活性缺陷，提示其在眼动神经元发育中的关键作用。
2. **文献名称**：*Expression and functional characterization of recombinant PHOX2A in neuroblastoma models*
**作者**：Delloye-Bourgeois C, et al.
**摘要**：利用重组PHOX2A蛋白探究其在神经母细胞瘤中的作用，发现其过表达可抑制肿瘤细胞增殖，并调控下游交感神经元分化相关基因(如DBH、TH)，为治疗提供了潜在靶点。
3. **文献名称**：*In vitro reconstitution of PHOX2A-DNA binding activity for genetic screening*
**作者**：Nakano M, et al.
**摘要**：开发了基于重组PHOX2A蛋白的体外DNA结合实验，用于快速筛查临床患者中导致DNA结合功能丧失的突变，为先天性面部麻痹的分子诊断提供了高效方法。
---
**备注**：PHOX2A研究相对集中于基础神经发育领域，直接涉及重组蛋白制备的文献较少。建议扩展检索至PHOX2A的同源蛋白(如PHOX2B)或相关疾病(如先天性中枢性低通气综合征)，以获取更多参考信息。
PHOX2A (paired mesoderm homeobox protein 2A) is a transcription factor encoded by the *PHOX2A* gene, belonging to the paired-like homeodomain family. It plays a critical role in the development of specific neuronal subsets, particularly in the autonomic nervous system. PHOX2A is essential for the differentiation and maintenance of noradrenergic neurons, including those in the locus coeruleus, retina, and cranial motor nuclei. It regulates genes involved in neurotransmitter synthesis, such as tyrosine hydroxylase and dopamine β-hydroxylase, thereby influencing autonomic signaling pathways. Mutations in *PHOX2A* are linked to congenital disorders like autosomal recessive congenital fibrosis of the extraocular muscles (CFEOM) and other neurocristopathies, highlighting its importance in neurodevelopment.
Recombinant human PHOX2A protein is produced via genetic engineering in systems like *E. coli* or mammalian cell cultures, ensuring high purity and bioactivity. This engineered protein retains DNA-binding capacity and transcriptional regulatory functions, enabling studies on neuronal differentiation mechanisms and disease modeling. Researchers utilize it to investigate PHOX2A’s interactions with downstream targets or its role in neural crest cell specification. Additionally, recombinant PHOX2A has potential therapeutic applications, such as in regenerative strategies for neurodegenerative conditions or congenital autonomic disorders. Its study also contributes to understanding epigenetic regulation in neurodevelopmental syndromes. Ongoing research aims to elucidate its broader regulatory networks and therapeutic utility.
×
